Opera Trading Capital’s Pfizer PFE Stock Holding History

Opera Trading Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-105	Closed	-$3K	–	167
2017 Q2	$3K	Buy	+105	New	+$3.31K	﹤0.01%	143

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Opera Trading Capital's PFE Position: Q3 2017 in Review

Opera Trading Capital sold out of Pfizer (PFE) in Q3 2017, closing a stake of 105 shares — an estimated $3K sold.

Opera Trading Capital first reported a position in PFE in Q2 2017 and held it in 1 quarter. The position peaked at $3K in Q2 2017. 2,042 funds tracked by Wall St. Rank hold PFE as of Q3 2017.

Opera Trading Capital reported no remaining Pfizer position as of Q3 2017 after selling out during the quarter.
Opera Trading Capital sold 105 Pfizer shares in Q3 2017, an estimated $3K.
Opera Trading Capital first reported a position in Pfizer in Q2 2017 and held it in 1 quarter.
Opera Trading Capital's Pfizer position peaked at $3K in Q2 2017.
2,042 funds tracked by Wall St. Rank held Pfizer as of Q3 2017.

Based on Opera Trading Capital's 13F filing for Q3 2017, filed 6 Nov 2017.